radioimmunotherapy rit combines advantages specific immunotherapy cytotoxicity radionuclides resulting targeted radiation therapy setting allogeneic hematopoietic cell transplantation hct rit used target tumor cells suppress immunocompetent recipient cells rit successfully used dose intensification myeloablative conditioning regimens hct short path length high linear energy transfer bear certain advantages used target hematopoietic cells using canine model hct demonstrate rit bismuth213 213bi coupled monoclonal antibodies mab immunosuppression mycophenolate mofetil cyclosporine achieve stable engraftment mixed chimerism mabs allow tailored approach rit conditioning used patients hematologic malignancies diseases extensive studies biodistribution dose toxicity provide basis conception clinical trials using rit hct references NUMBER beta emitters alpha emitters beta emitters non myeloablative pre transplant alpha emitter anti cd45 anti tcralphabeta post grafting long term non myeloablative 213bi anti cd45 213bi anti tcralphabeta non malignant escalation non myeloablative